Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Haemonetics SmartSuction technology:

This article was originally published in Clinica

Executive Summary

Haemonetics has launched in the US an automated surgical suction device that it claims enhances a surgeon's ability to clear fluids from the surgical field by providing high air flow and self-regulating suction. The SmartSuction Solo system, which received 510(k) clearance last month, is the first product that Haemonetics will sell into the general surgery market, expanding its market opportunity by an incremental $240m, says the Braintree, Massachusetts company. It is the third system developed by the firm under its SmartSuction family of products, and marks a milestone in Haemonetics' efforts to expand from a surgical blood salvage company into a broader blood management company, the firm adds. The company acquired the technology from Harvest Technologies in 2004 (see Clinica No 1123 p 14).

You may also be interested in...



COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel